Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors

The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers

(2020) A. Yver et al.   ANNALS OF ONCOLOGY

Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance

(2020) Seiichiro Mitani et al.   Cancers

Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study)

(2020) Akitaka Makiyama et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II study of efficacy and safety of RC48-ADC in patients with locally advanced or metastatic HER2-overexpressing gastric or gastroesophageal junction cancers.

(2020) Zhi Peng et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

(2020) Kohei Shitara et al.   NEW ENGLAND JOURNAL OF MEDICINE

Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer

(2020) Michelle D. Hackshaw et al.   BREAST CANCER RESEARCH AND TREATMENT

A phase II study of RC48-ADC in HER2-positive patients with locally advanced or metastatic urothelial carcinoma.

(2019) Xinan Sheng et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study

(2019) Kohei Shitara et al.   LANCET ONCOLOGY

Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer

(2018) De-Shen Wang et al.   GUT

Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study

(2018) Josep Tabernero et al.   LANCET ONCOLOGY

Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604)

(2018) Hiroshi Saeki et al.   EUROPEAN JOURNAL OF CANCER

Antibody drug conjugates under investigation in phase I and phase II clinical trials for gastrointestinal cancer

(2018) Alexis D. Leal et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study

(2017) Peter C Thuss-Patience et al.   LANCET ONCOLOGY

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study

(2017) Toshihiko Doi et al.   LANCET ONCOLOGY

An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer

(2016) Hongwen Li et al.   CANCER BIOLOGY & THERAPY

Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial

(2016) J. Randolph Hecht et al.   JOURNAL OF CLINICAL ONCOLOGY

Quantitative characterization of in vitro bystander effect of antibody-drug conjugates

(2016) Aman P. Singh et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice

(2016) Federica Grillo et al.   WORLD JOURNAL OF GASTROENTEROLOGY

HER2 Gene Amplification by Fluorescence In Situ Hybridization (FISH) Compared With Immunohistochemistry (IHC) in 122 Equivocal Gastric Cancer Cases

(2016) Xiaoyan Liu et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity

(2015) Xuejing Yao et al.   BREAST CANCER RESEARCH AND TREATMENT

Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment ofHER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study

(2014) Taroh Satoh et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET